Zim Laboratories Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/61duaqtr0dmwgvxebbt7v4db.pdf

Key Takeaways


EU-GMP Inspection: The Core Setback

C. Mainde: "The critical observations are given where we need to have a go for the re-inspection. In our case, we are using a manual system for the documentation... the German auditors who visited they've taken a view that it will be better to have an electronic regulatory system."

EU Commercialization: Paths to Market

Anwar Daud: "There is a third opportunity where the products which are in short supply in some markets, if the partners so wish, they can obtain special permission to supply to special approvals for such products, and the supplies can continue if the partners are willing to trigger these kind of approvals."

Q1 Performance: Geopolitics and Mix

Anwar Daud: "Unfortunately, for us, the entire the work that we have done in the last 5 years is just entering that phase of an interesting phase for the company. And we are waiting, and we have partners who also believe in us."

Partnerships and Product Pipeline


Base Business and Revenue Outlook

Anwar Daud: "We are saying we are delayed by 6 to 9 months. But the processes are, they come a little late. So probably in the end, we might end up with a few months loss at the most."

Guidance & Commitments

CommitmentSpecificsTimeline
CAPA submissionSubmit corrective and preventive action plan to EU authoritiesAugust 31, 2025
EU-GMP resolutionComplete all rectification activities and achieve compliance8-9 months
ReinspectionReceive EU reinspection of the facilityWithin 6 months
Alternate site readinessSecure TGA-approved alternate site for product transfer3 months for approval
Base business growthAchieve similar growth as last year on base business (ex-EU upside)FY26
EU commercializationEU revenue upside realization shifts out of current yearPushed to FY27
Neuraxpharm launchPartner launch from ZIM's plantLast two quarters of CY26 (FY26)
Exact guidanceProvide detailed revenue guidancePost H1 FY26
Tamsulosin Australia launchMarketing through licensed partner, possibly via alternate sitePossibly last quarter FY26

Key Metrics

MetricQ1 FY26
Total operating income₹71.8 cr, down 12.3% YoY from ₹81.8 cr in Q1 FY25
EBITDA₹5.7 cr, margin of 7.9%, down 36.7% YoY
Net profit / lossNet loss of ₹1.9 cr, against a profit of ₹0.9 cr in Q1 FY25
Pharma segment share78% of revenue, Nutra at 22%
Export revenue₹60.2 cr, down 15.2% YoY from ₹70.9 cr in Q1 FY25
Domestic revenue₹10 cr, up 30.2% YoY
NIP and OTF revenue₹4.6 cr, comprising ₹1.2 cr from NIP and ₹3.4 cr from OTF, 6.2% of operating income
NIP and OTF contribution including license fees12.9% of operating income
NIP license income₹4 cr
R&D spend₹7.9 cr, including ₹1.9 cr for BE studies and registrations
NIP products in pipeline12 in progress, 8 filed in EU
Middle East revenue share~30%, similar to last year
CAPA implementation timeline6 to 9 months from company side, 8 to 9 months total for all activities
Commercialization timeline shiftDelayed by 3 to 6 months, now expected in FY26